Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Solid Tumors
Interventions: DRUG: Alisertib|DRUG: MLN0128
Sponsor: University of Colorado, Denver